US 4,075,335 AGrant
Pharmaceutical Piperidine Derivatives
Issue Date:1978-02-21
•13 Claims
Abstract
Piperidines of the formula ##STR1## in which R.sub.1 stands for optionally substituted aryl, R.sub.2 for hydrogen, lower alkyl, lower alkenyl, acyl or .alpha.-aryl-lower alkyl, R.sub.3 for a free or substituted hydroxyl group, alk for lower alkylene which separates the two nitrogen atoms by 2 or 3 carbon atoms, R.sub.4 represents hydrogen or lower alkyl and n represents an integer from 1 to 4, and their salts as well as processes for their manufacture and pharmaceutical compositions comprising such compounds, and a process for lowering the blood pressure wherein such compositions are administered to a warm-blooded host.
Metadata
Assignee
- Ciba-Geigy Corporation
Inventors
- Max Wilhelm
- Kurt Eichenberger
- Herbert Schroter
- Franz Ostermayer
Application Information
Application Number:US 6529666
Filing Date:1976-01-28
Priority Date:1972-08-24
Art Unit:125
Classifications
IPC:
A61K 3133
Field of Search:
424246;267;274;285;244
Patent Drawings
This patent does not have any drawings.
Description
EXAMPLE 1
A solution of 10 g of 1-(o-methoxy-phenoxy)-2,3-epoxypropane and 10 g of 1-[piperidyl-(4)]-imidazolidinone-(2) in 50 ml of ethanol is warmed to 80.degree. C for 4 hours and then evaporated in vacuo. The residue is dissolved in 100 ml of 2 N hydrochloric acid, the solution is extracted with ether and the aqueous phase is rendered alkaline by adding 10 N sodium hydroxide solution. 1-{1-[3-(o-Methoxy-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidi none-(2) separates out and after recrystallisation from ethanol melts at 138.degree. C. The hydrochloride melts at 158.degree.-160.degree. C.
1-[Piperidyl-(4)]-imidazolidinone-(2) used as the starting material can be manufactured as follows:
55 g of .beta.-chloroethyl isocyanate are added dropwise to a solution of 47 g of 4-aminopyridine in 200 ml of dimethylformamide and the mixture is stirred for 1 hour. On adding 400 ml of water, N-(4-pyridyl)-N'-.beta.-chloroethylurea precipitates and after recrystallisation from alcoholwater melts at 120.degree.-122.degree. C.
66 g of N-(4-pyridyl)-N'-.beta.-chloroethyl-urea are heated with a solution of 12 g of sodium ethylate in 400 ml of ethanol under reflux for 2 hours. 1-(4-Pyridyl)-imidazolidinone-(2) precipitates, and melts at 205.degree.-206.degree. C.
15 g of 1-(4-pyridyl)-imidazolidinone-(2) in 150 ml of alcohol are hydrogenated in the presence of 1.5 g of ruthenium on charcoal (10 percent strength) at 150.degree. C and under a pressure of 150 atmospheres gauge pressure. After the absorption of hydrogen has ceased, the catalyst is filtered off, the filtrate is evaporated to dryness and the residue is recrystallised from methylene chloride/petroleum ether. 1-[Piperidyl-(4)]-imidazolidinone-(2) is obtained in crystals of melting point 154.degree.-158.degree. C.
EXAMPLE 2
15 g of 1-(m-methoxy-phenoxy)-2,3-epoxy-propane and 15 g of 1-[piperidyl-(4)]-imidazolidinone-(2) in 30 ml of ethanol are warmed to 80.degree. C for 4 hours and the mixture is then evaporated in vacuo. The residue is treated with 100 ml of 2 N hydrochloric acid and extracted with ether. The aqueous layer is then reduced alkaline by adding 10 N sodium hydroxide solution and is extracted with methylene chloride. After evaporation of the solvent, 1-{1-[3-(m-methoxy-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidi none-(2) is obtained as a viscous oil of which the fumarate melts at 192.degree.-193.degree. C.
EXAMPLE 3
A solution of 15 g of 1-(p-allyloxy-phenoxy)-2,3-epoxy-propane and 15 g of 1-[piperidyl-(4)]-imidazolidinone-(2) in 30 ml of alcohol is warmed to 90.degree. C for 4 hours and subsequently evaporated in vacuo. The residue is dissolved in 2 N hydrochloric acid, the solution is extracted with ether and 10 N sodium hydroxide solution is added to the aqueous phase until it gives an alkaline reaction. After extraction with methylene chloride and evaporation of the solvent, 1-{1-[3-(p-allyloxyphenoxy)-2-hydroxy-1-propyl]-piperidyl(4)}-imidazolidin one-(2) is left; after recrystallisation from ethanol it melts at 132.degree.-3.degree. C. The methanesulphonate melts at 154.degree.-157.degree. C.
EXAMPLE 4
10 g of 1-{1-[3-(p-benzyloxy-phenoxy)-2-hydroxy-1-propyl)-piperidyl-(4)}-imidazoli dinone-(2) in 200 ml of methanol are hydrogenated in the presence of 1 g of palladium on charcoal (5 percent strength) at room temperature and under normal pressure. After the hydrogen uptake has ceased, the catalyst is filtered off and the solvent is evaporated. 1-{1-[3-(p-Hydroxy-phenoxy)-2-hydroxy-1-propyl)-piperidyl-(4)}imidazolidin one-(2) is left; its hydrochloride melts at 238.degree. C.
In analogous manner, the hydrogenation of 1-[3-(o-benzyloxyphenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-pipe ridine yields the 1-[3-(o-hydroxyphenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-piperi dine, which melts at 183.degree.-185.degree. C.
EXAMPLE 5
Warming 15 g of 1-(p-benzyloxy-phenoxy)-2,3-epoxypropane and 15 g of 1-(4-piperidyl)-2-imidazolidinone in 30 ml of ethanol to 80.degree. C and subsequently evaporating the solvent yields 1-{1-[3-(p-benzyloxyphenyl)-2-hydroxy-1-propyl)-piperidyl-(4)}-imidazolidi none-(2), which melts at 166.degree. C.
The 1-[3-(o-benzyloxy-phenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-pip eridine can be manufactured in analogous manner.
EXAMPLE 6
A mixture of 15 g of 1-(p-acetamino-phenoxy)-2,3-epoxy-propane, 15 g of 1-(4-piperidyl)-2-imidazolidinone and 30 ml of alcohol is warmed to 80.degree. C for 3 hours and then evaporated in vacuo. The residue is dissolved in 2 N hydrochloric acid and extracted with ether, and the aqueous phase is then rendered alkaline by adding 10 N sodium hydroxide solution. 1-{1-[3-(p-Acetamido-phenoxy)-2-hydroxy-1-propyl]-piperidyl(4)}-imidazolid inone-(2) precipitates and after recrystallisation from ethanol melts at 162.degree.-165.degree. C. The hydrochloride melts at 257.degree.-259.degree. C.
EXAMPLE 7
A mixture of 15 g of 1-(o-allyl-phenoxy)-2,3-epoxypropane, 15 g of 1-(4-piperidyl)-2-imidazolidinone and 30 ml of alcohol is warmed to 80.degree. C for 4 hours and subsequently evaporated. The residue is dissolved in 200 ml of 2 N hydrochloric acid and extracted with ether, and the aqueous phase is then rendered alkaline by adding 10 N sodium hydroxide solution. 1-{1-[3-(o-Allyl-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidino ne-(2) separates out as an oil. The hydrochloride melts at 186.degree.-189.degree. C.
EXAMPLE 8
A mixture of 15 g of 1-(o-allyloxy-phenoxy)-2,3-epoxy-propane, 15 g of 1-(4-piperidyl)-2-imidazolidinone and 45 ml of ethanol is warmed to 90.degree. C for 4 hours and then evaporated in vacuo. The residue is dissolved in 200 ml of 2 N hydrochloric acid, the solution is extracted with ether and the aqueous phase is then rendered alkaline by adding concentrated sodium hydroxide solution. The 1-{1-[3-(o-allyloxyphenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidi none-(2) which has precipitated is extracted by shaking with methylene chloride. The oil which remains after drying and evaporating the methylene chloride is dissolved in 44 ml of ethanol. After adding 10.5 g of cyclohexylsulphamic acid, crystals of the cyclohexylsulphamate separate out; these melt at 128.degree.-130.degree. C after recrystallisation from ethanol.
EXAMPLE 9
A solution of 30 g of 1-(o-methoxy-phenoxy)-2,3-epoxypropane and 30 g of 1-[piperidyl-(4)]-3-methyl-imidazolidinone in 100 ml of ethanol is warmed to 90.degree. C for 3 hours and evaporated in vacuo. The residue is dissolved in 100 ml of 2 N hydrochloric acid, the solution is extracted with ether and the aqueous phase is rendered alkaline by adding 10 N sodium hydroxide solution. After extraction with methylene chloride and evaporation of the solvent, 1-{1-[3-(o-methoxy-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-3-methyl-im idazolidinone-(2) remains as an oil. After recrystallisation from ethanol/ether, the hydrochloride melts at 172.degree. C.
1-[Piperidyl-(4)]-3-methyl-imidazolidinone, required as the starting material, can be manufactured by hydrogenation of 1-(4-pyridyl)-3-methyl-imidazolidinone-(2) with ruthenium as the catalyst. The compound melts at 60.degree.-64.degree. C.
EXAMPLE 10
Analogously to the description in Example 1, 1-(p-N-methylcarbamoyl-phenoxy)-2,3-epoxy-propane and 1-[piperidyl-(4)]-imidazolidinone-(2) yield 1-{1-[3-(p-N-methylcarbamoylphenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-im idazolidinone-(2), which after recrystallisation from ethyl acetate melts at 180.degree.-182.degree. C, and of which the neutral fumarate, after recrystallisation from methanol/ether melts at 191.degree.-196.degree. C.
EXAMPLE 11
Analogously to the description in Example 1, 1-(o-methyl-phenoxy)-2,3-epoxy-propane and 1-[piperidyl-(4)]-imidazolidinone-(2) yield 1-{1-[3-(o-methyl-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidin one-(2) of melting point 114.degree.-116.degree. C.
EXAMPLE 12
Analogously to the description in Example 1, 1-(o-chloro-phenoxy)-2,3-epoxy-propane and 1-[piperidyl-(4)]-imidazolidinone-(2) yield 1-{1-[3-(o-chloro-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidin one-(2) of melting point of 150.degree.-151.degree. C, of which the neutral fumarate, when recrystallised from methanol/ether, melts at 172.degree.-173.degree. C (sintering from 170.degree. C onwards).
EXAMPLE 13
Analogously to the description in Example 1, 1-(2-methoxy-4-N-methylcarbamoyl-phenoxy)-2,3-epoxy-propane and 1-[piperidyl-(4)]-imidazolidinone-(2) yield 1-{1-[3-(2-methoxy-4-N-methylcarbamoyl-phenoxy)-2-hydroxy-1-propyl]-piperi dyl-(4)}-imidazolidinone-(2) which after recrystallisation from isopropanol melts at 104.degree.-107.degree. C.
EXAMPLE 14
A solution of 6.56 g of 1-(o-tolyloxy)-2,3-epoxy-propane and 7.7 g of 1-[piperidyl-(4)]-2-oxo-hexahydro-pyrimidine in 5 ml of ethanol is heated of 31/2 hours at a bath temperature of 95.degree. C and then evaporated in vacuo. The residue is triturated with ethyl acetate, whereupon crystallisation commences. The crystals are stirred with water and filtered off. Recrystallisation from ethyl acetate/petroleum ether yields the 1-[3-(o-tolyloxy)-2-hydroxy-propyl]-4-(2-oxo-hexahydro-1-pyrimidinyl)-pipe ridine which melts at 145.degree.-147.degree. C.
The 1-[piperidyl-(4)]-2-oxo-hexahydro-pyrimidine used as starting material can be prepared as follows:
At room temperature, 30 g of .gamma.-chloro-propyl-isocyanate are added dropwise over the course of 2 hours to a solution of 18.8 g of 4-amino-pyridine in 80 ml of dimethyl formamide and stirring is continued for 24 hours. After the dimethyl formamide has been evaporated off in a water jet vacuum at 80.degree. C, 4.27 g of the residue are dissolved in 25 ml of methanol and this solution is treated at boiling heat over the course of 20 minutes with a solution of 1.19 g of sodium methylate in 25 ml of methanol with stirring. The reaction mixture is then refluxed for 1 hour. The precipitated sodium chloride is filtered off, the filtrate is evaporated in vacuo and the residue is recrystallised from chloroform/petroleum ether to yield the 1-[pyridyl-(4)]-2-oxo-hexahydro-pyrimidine which melts at 180.degree.-182.degree. C.
17.7 g of 1-[pyridyl-(4)]-2-oxo-hexahydro-pyrimidine are hydrogenated in 180 ml of water in the presence of 2. 5 g of ruthenium on charcoal catalyst (10%) at 120.degree. C and an atmospheric excess pressure of 120. After the uptake of hydrogen has ceased, the catalyst is filtered off and the filtrate is evaporated to dryness. Recrystallisation from chloroform/petroleum ether yields the 1-[piperidyl-(4)]-2-oxo-hexahydro-pyrimidine (m.p. 207.degree.-210.degree. C).
EXAMPLE 15
A solution of 9 g of 1-(o-methoxy-phenoxy)-2,3-epoxypropane and 9.15 g of 1(4-piperidyl)-2-oxo-hexahydro-pyrimidine in 7 ml of abs. ethanol is heated for 5 hours to 95.degree. C and then evaporated in vacuo. The residue is recrystallised from ethyl acetate/petroleum ether to yield the 1-[3-(o-methoxyphenoxy)-2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidinyl) -piperidine, which melts at 130.degree.-133.degree. C.
A solution of 17.1 g of the above base in 100 ml of abs. ethanol is added to a solution of 5.5 g of furamic acid in 105 ml of abs. ethanol. The 1-[3-(o-methoxyphenoxy)-2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidinyl) -piperidine fumarate (1:1) precipitates on the addition of ether; m.p. 149.degree.-151.degree. C.
EXAMPLE 16
A solution of 10.4 g of 1-[p-(2-methoxyethyl)-phenoxy]-2,3-epoxy-propane and 9.15 g of 1-(4-piperidyl)-2-oxo-hexahydropyrimidine in 7 ml of abs. ethanol is heated for 5 hours to 95.degree. C and then evaporated in vacuo. The residue is recrystallised from ethyl acetate/petroleum ether to yield the 1-[3-(p-(2-methoxyethyl)-phenoxy)-2-hydroxypropyl]4-(2-oxo-hexahydro-1-pyr imidinyl)-piperidine, which melts at 113.degree.-115.degree. C.
A solution of 18.5 g of the base described above in 30 ml abs. ethanol is added to a solution of 5.5 g of furmaric acid in 105 ml of absolute ethanol. The 1-[3-(p-(2-methoxyethyl)-phenoxy)-2-hydroxypropyl]- 4-(2-oxo-hexahydro-1-pyrimidinyl)-piperidine fumarate (2:1) precipitates on the addition of ether; m.p. 157.degree.-159.degree. C.
Example 17
A solution of 19.35 g of 1-(p-acetamido-phenoxy)-2,3-epoxy-propane and 9.15 g of 1-(4-piperidyl)-2-oxo-hexahydropyrimidine in 10 ml of abs. ethanol is heated to 95.degree. C. The reaction product crystallises out at boiling heat after about 5 minutes. The crystal broth is diluted with 10 ml of abs. ethanol and heated for a further 5 hours. When the reaction is terminated the batch is evaporated in vacuo and the residue is recrystallised from abs. ethanol/ether to yield the 1-[3-(p-acetamido-phenoxy)-2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidin yl)-piperidine, which melts at 218.degree.-221.degree. C.
EXAMPLE 18
A solution of 9.2 g of 1-(o-chloro-phenoxy)-2,3-epoxy-propane and 9.15 g of 1-(4-piperidyl)-2-oxo-hexahydro-pyrimidine in 7 ml of abs. ethanol is heated for 5 hours to 95.degree. C and then evaporated in vacuo. The residue is recrystallised from chloroform/petroleum ether to yield the 1-[3-(o-chloro-phenoxy)-2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidinyl) -piperidine, which melts at 150.degree.-153.degree. C.
A solution of 12.7 g of the above base in 60 ml of abs. ethanol is added to a solution of 4.05 g of furmaric acid in 77 ml of abs. ethanol. The 1-[3-(o-chlorophenoxy)-2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidinyl)- piperidine fumarate (2:1) precipitates on the addition of ethyl acetate and ether; m.p. 169.degree.-171.degree. C.
EXAMPLE 19
A solution of 10.3 g of 1-(o-allyloxy-phenoxy)-2,3-epoxy-propane and 9.15 g of 1-(1-(4-piperidyl)-2-oxo-hexahydropyrimidine in 7 ml abs. ethanol is heated for 5 hours to 95.degree. C and then evaporated in vacuo. The residue is recrystallised from isopropanol to yield the 1-[3-(o-allyloxy-phenoxy)-2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidiny l)-piperidine, which melts at 122.degree.-125.degree.C.
A solution of 8.45 g of the above base in 50 ml of abs. ethanol is added to a solution of 2.52 g of fumaric acid in 50 ml of abs. ethanol. The 1-[3-o-allyloxy-phenoxy)-2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidinyl )-piperidine fumarate (1:1) precipitates on addition of ether; m.p. 154.degree.-156.degree. C.
EXAMPLE 20
A solution of 10.8 g of 1(p-methoxy-phenoxy)-2,3-epoxypropane and 10.15 g of 1-(4-piperidyl)-imidazolidin-(2)-one in 10 ml of abs. ethanol is heated for 5 hours to 95.degree. C and then evaporated in vacuo. The residue is dissolved in 80 ml of 2 normal hydrochloric acid. Extraction is performed with methylene chloride and the aqueous phase is then made alkaline by addition of a concentrated aqueous sodium hydroxide solution. Extraction with methylene chloride and then evaporation of the solvent yields the 1-[3-(p-methoxy-phenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-piper idine, which melts at 148.degree.-150.degree. C after recrystallisation form isopropanol.
13.7 g of the above base are dissolved in 40 ml of abs. ethanol by warming. The solution is added to 20.7 ml of a 1.9 N ethanolic solution of hydrochloric acid. The 1-[3-(p-Methoxyphenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-piperi dine hydrochlorid precipitates on cooling. It melts at 209.degree.-211.degree. C.
EXAMPLE 21
A solution of 0.50 g of 1-[3-(o-hydroxy-phenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazoldinyl)-piperi dine in 20 ml of dimethylformamide is treated with 65 mg of sodium hydride suspension (55% in paraffin oil) and the mixture is stirred for 1 hour at 20.degree.-30.degree. C. Then 0.23 g of methyl idoide is added and the reaction mixture is stirred for 18 hours at 20.degree.-30.degree. C. The solvent is evaporated off in vacuo and the residue is then washed with 5 ml of pentane. The undissolved substance is partitioned between 30 ml of ethyl acetate and 3 ml of 6 normal sodium hydroxide solution. The organic phase is extracted once more with 3 ml of 6 normal sodium hydroxide solution, dried over magnesium sulphate and evaporated in vacuo, to yield 0.45 g of a yellow oil. Recrystallisation from ethanol yields pure 1-[3-(o-methoxyphenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-piperi dine with a melting point of 138.degree. C (melting point of the hydrochloride: 158.degree.-160.degree. C). Thin-layer chromatography shows the product to be identifical with that described in Example 1.
EXAMPLE 22
Tablets containing 25 mg of 1-{1-[3-(o-methoxy-phenoxy)2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidin one-(2) can, for example, be manufactured to have the following composition:
MANUFACTURE
The active compound is mixed with the lactose, the colloidal silica and a part of the wheat starch and the mixture is forced through a sieve. A further part of the wheat starch is worked into a paste with a 5-fold amount of water on a water bath and the powder mixture is kneaded with this paste until a slightly plastic mass has been produced.
The mass is forced through a sieve and dried and the dry granules are again sieved. Thereafter, the remaining wheat starch, the talc and the magnesium stearate are mixed in and the mixture is pressed to give tablets weighing 100 mg, having a breaking groove.
EXAMPLE 23
Tablets containing 15 mg of 1-{1-[3-(o-methoxyphenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidin one-(2) and 10 mg of .beta.-(1-azacyclooctyl)-ethylguanidine sulphate.
MANUFACTURE
The active compound is mixed with the lactose, the colloidal silica and a part of the wheat starch and the mixture is forced through a sieve. A further part of the wheat starch is worked into a paste with a 5-fold amount of water on a water bath and the powder mixture is kneaded with this paste until a slightly plastic mass has been produced.
The mass is forced through a sieve and dried and the dry granules are again sieved. Thereafter, the remaining wheat starch, the talc and the magnesium stearate are mixed in and the mixture is pressed to give tablets weighing 100 mg, having a breaking groove.
EXAMPLE 24
Tablets containing 25 mg of 1-{1-[3-(o-methoxyphenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidin one-(2) and 25 mg of 6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide.
MANUFACTURE
The active compound is mixed with the lactose, the collodial silica and a part of the wheat starch and the mixture is forced through a sieve. A further part of the wheat starch is worked into a paste with a 5-fold amount of water on a water bath and the powder mixture is kneaded with this paste until a slightly plastic mass has been produced.
The mass is forced through a sieve and dried and the dry granules are again sieved. Thereafter, the remaining wheat starch, the talc and the magnesium stearate are mixed in and the mixture is pressed to give tablets weighing 125 mg, having a breaking groove.
EXAMPLE 25
Tablets containing 25 mg of 1-[3-(o-methoxyphenoxy)-2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidinyl) -piperidine can be manufactured e.g. in the following composition:
MANUFACTURE
The active substance is mixed with the lactose, the colloidal silicic acid and a portion of the wheat starch and the mixture is passed through a sieve. A further portion of the wheat starch is pasted on a water bath with the 5-fold amount of water and the powder mixture is kneaded with the resulting paste until a slightly plastic mass is obtained. This mass if forced through a sieve, dried, and the dry granules are then sieved. The remainder of the wheat starch, the talcum and the magnesium stearate are then admixed and the mixture is pressed into tablets weighing 100 mg with breaking notch.
EXAMPLE 26
Tablets containing 15 mg of 1-[3-(o-tolyloxy)-2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidinyl)-piper idine and 10 mg of .beta.-(1-azacyclooctyl)-ethyl-guanidine sulphate can be manufacture e.g. in the following composition:
Tablets weighing 100 mg with breaking notch are manufactured by carrying out the procedure as described in Example 25.
EXAMPLE 27
Tablets containing 25 mg of 1-[3-(o-methoxyphenoxy)2-hydroxypropyl]-4-(2-oxo-hexahydro-1-pyrimidinyl)- piperdine can be manufactured e.g. in the following composition:
Tablets weighing 125 mg with breaking notch are manufactured by carrying out the procedure as described in Example 25.
Claims
We claim:
1. A pharmaceutical composition useful in treating hypertension and tachycardia which comprises an anti-hypertensively and anti-tachycardially effective amount of a piperidine compound having the formula ##STR14## wherein R.sub.1 is phenyl, naphthyl, 5,6,7,8-tetrahydro-1-naphthyl or 5,6,7,8-tetrahydro-2-naphthyl radical which is unsubstituted, monosubstituted or disubstituted by lower alkyl, lower alkoxy, lower alkenyl, lower alkenyloxy, halogen, halogeno-lower alkyl, carbamoyl, lower alkyl-substituted carbamoyl, lower alkoxycarbonylamino-lower alkyl, lower alkoxy-lower alkoxy, lower alkanoylaminoethenyl, lower alkylthio-lower alkoxy, hydroxyl, lower alkanoyl, lower alkoxy-lower alkyl, lower alkynyl, lower alkylthio-lower alkyl, hydroxy-lower alkyl, lower alkanoyloxy, lower alkylthio, lower alkanoyl amino, cyano, amino, nitro, ureido, lower alkylated ureido, phenyl-lower alkoxy, or lower alkynyloxy, R.sub.2 is hydrogen, lower alkyl, lower alkenyl, .alpha.-phenyl-lower alkyl or lower alkanoyl, R.sub.3 is a free hydroxyl group, a lower alkanoyloxy group or a lower alkoxy group, R.sub.4 is hydrogen or lower alkyl, n is an integer from 0 to 4, and alk is an optionally mono-lower alkylated ethylene radical or a salt thereof, together with a therapeutically useful carrier.
2. The pharmaceutical composition of claim 1, wherein the active compound has the formula defined in claim 1, wherein R.sub.1 is a phenyl radical mono- or di-substituted by lower alkyl, lower alkoxy, lower alkenyl, lower alkenyloxy, lower alkanoyl, lower alkanoylamino, hydroxyl, benzyloxy, N-lower alkylcarbamoyl or halogen, R.sub.2 is hydrogen or lower alkyl, R.sub.3 is hydroxyl, R.sub.4 is hydrogen or methyl, n is 1 and alk is an optionally monomethylated ethylene radical.
3. The pharmaceutical composition of claim 1, wherein the active compound has the formula defined in claim 1, wherein R.sub.1 is phenyl monosubstituted by methyl, methoxy, allyl, allyloxy, hydroxyl, acetylamino, propionyl, N-methyl-carbamoyl or chlorine, R.sub.2 is hydrogen, R.sub.3 is hydroxyl, R.sub.4 is hydrogen and alk is ethylene.
4. The pharmaceutical composition of claim 1, wherein the active compound has the formula ##STR15## in which R' stands for halogen, lower alkyl or lower alkoxy, R" for lower alkyl or hydrogen, R''' for methyl or hydrogen and alk' for ethylene or an acid addition salt thereof.
5. The pharmaceutical composition of claim 1, wherein the active compound has the formula ##STR16## in which R' stands for lower alkyl or lower alkoxy and alk' for ethylene or an acid addition salt thereof.
6. The pharmaceutical composition of claim 1, wherein the active compound is 1-[3-(o-chlorophenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-pipe ridine or an acid addition salt thereof.
7. The pharmaceutical composition of claim 1, wherein the active compound is 1-[3-(o-methylphenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-pipe ridine or an acid addition salt thereof.
8. The pharmaceutical composition of claim 1, wherein the active compound is 1-[3-(o-methoxyphenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-pip eridine or an acid addition salt thereof.
9. A pharmaceutical composition useful in treating hypertension and tachycardia which comprises a therapeutically effective amount of a piperidine compound defined in claim 1 and a therapeutically effective amount of an anti-hypertensive agent selected from the group consisting of .alpha.-amino-.alpha.-methyl-.beta.-(3,4-dihydroxyphenyl)-propionic acid, .beta.-amino-.alpha.-(3,4-dimethoxy-phenyl)-propionic acid, 1,4-dihydrazinophthalazine, 1-hydrazinophthalazine, 2-[(N-p-tolyl)-N-(m-hydroxyphenyl)-aminomethyl]-imidazoline or .beta.-(1-azacyclooctyl)-ethylguanidine.
10. The pharmaceutical composition as claimed in claim 9, containing 1-{1-[3-(o-methoxy-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidi none-(2) together with 1-.alpha.-amino-.alpha.-methyl-.beta.-(3,4-dihydroxyphenyl)-propionic acid or .beta.-(1-azacyclooctyl)-ethylguanidine sulphate.
11. A pharmaceutical composition useful in treating hypertension and tachycardia which comprises a therapeutically effective amount of a piperidine compound defined in claim 1 and a therapeutically effective amount of a diuretic selected from the group consisting of 6-chloro-7-sulphamyl-1,2,4-benzothiadiazine-1,1-dioxide, 6-trifluoromethyl-7-sulphamyl-1,2,4-benzothiadiazine-1,1-dioxide, 2-benzylthiomethyl-6-chloro-7-sulphamyl-1,2,4-benzothiadiazine-1,1-dioxide , 3-ethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxi de, 3-trichloromethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine- 1,1-dioxide, 3-benzyl-6-trifluoromethyl-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine- 1,1-dioxide, 2-methyl-3-(2,2,2-trifluoroethylthiomethyl)-6-chloro-7-sulphamyl-3,4-dihyd ro-1,2,4-benzothiadiazine-1,1-dioxide, 3-(2,2,2-trifluoroethylthiomethyl)-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4- benzothiadiazine-1,1-dioxide, 3-(5-norbornen-2-yl)-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazi ne-1,1-dioxide, 2-methyl-3-chloromethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadi azine-1,1-dioxide, 6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 3-dichloromethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1 ,1-dioxide, 3-cyclopentylmethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazin e-1,1-dioxide, 6-trifluoromethyl-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxi de and 3-isobutyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dio xide.
12. Pharmaceutical composition as claimed in claim 11, containing 1-{1-[3-(o-methoxy-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidi none-(2) together with 1-oxo-3-(3-sulphamyl-4-chloro-phenyl)-3-hydroxyisoindoline, 6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 3-cyclopentylmethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazin e-1,1-dioxide or 5-(2-methylenebutyryl)-6-methyl-benzofurane2-carboxylic acid.
13. A method for the treatment of hypertension of tachycardia which comprises administering to a mammal afflicted therewith a pharmaceutical composition according to claim 1.